A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats

McEachern, Jennifer A.; Bingham, John; Crameri, Gary; Green, Diane J.; Hancock, Tim J.; Middleton, Deborah; Feng, Yanru; Broder, Christopher C.; Wang, Lin‐Fa; Bossart, Katharine N.

doi:10.1016/j.vaccine.2008.05.016

Cited by 114 publications

(103 citation statements)

References 28 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Gross lesions include increased pulmonary edema, hydrothorax, edematous pulmonary lymph nodes, petechial hemorrhages, serosanguineous pleural fluid, mediastinal edema, froth in the bronchi, and dense red areas of consolidation in the lung. 34,47,49,50 Less frequent gross lesions include edema of the bladder wall and mild jaundice. 49 Histologically, vasculitis affects multiple sites, with endothelial syncytial cell formation.…”

Section: The Brain Is a Major Target Of Niv Infection In Hamstersmentioning

confidence: 99%

“…5 Work by Mungall 50 and Bossart 5 indicates that a HeV-derived vaccine would protect against HeV and NiV. 47 A canarypox NiV vaccine was protective in pigs, and it restricted virus replication and nasal and pharyngeal shedding, thereby limiting the chance for spread of the virus to uninfected animals. 77 Furthermore, one report suggested that NiV F and G proteins may be involved in inducing CD8þ cytotoxic T-cell response to NiV.…”

Section: Antiviral Therapeutics and Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Henipavirus: A Review of Laboratory Animal Pathology

Williamson¹,

Torres-Vélez

2010

Vet Pathol

View full text Add to dashboard Cite

The genus Henipavirus contains two members-Hendra virus (HeV) and Nipah virus (NiV)-and each can cause fatal disease in humans and animals. HeV and Niv are currently classified as biosafety level 4, and NiV is classified as a category C priority pathogen. The aim of this article is to discuss the pathology of laboratory animal models of henipavirus infection and to assess their suitability as animal models for the development and testing of human therapeutics and vaccines. There has been considerable progress in the development of animal models for henipavirus disease. Suitable animal models include the golden hamster, ferrets, cats, and pigs, which develop disease resembling that observed in humans. Guinea pigs are a less reliable model for henipavirus disease, but they do develop henipavirus-induced encephalitis. Because human efficacy studies with henipaviruses are not permitted, animal studies are critical for the development of antiviral therapeutics and vaccines. Current research indicates that passive immunotherapy using monoclonal antibodies is protective of ferrets against NiV infection and that passive immunotherapy using NiV antibodies protects hamsters from HeV. Recombinant vaccines have been used to protect cats and pigs against NiV infection. Ribavirin and 6-aza-uridine were able to delay but not prevent NiV-induced mortality in hamsters. Further research is needed to develop a model and therapy for late-onset henipavirus encephalitis.

show abstract

Section: The Brain Is a Major Target Of Niv Infection In Hamstersmentioning

confidence: 99%

Section: Antiviral Therapeutics and Vaccinesmentioning

confidence: 99%

Henipavirus: A Review of Laboratory Animal Pathology

Williamson¹,

Torres-Vélez

2010

Vet Pathol

View full text Add to dashboard Cite

show abstract

“…A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. 36 ALVAC Canary pox vectored Nipah F and G vaccine appears to be a promising vaccine for swine and has potential as a vaccine for humans. 37 Cholesterol group is added to HRC peptides against Nipah virus targets to enhance their antiviral effect.…”

Section: Controlling Infection In Health-care Settingsmentioning

confidence: 99%

Nipah Virus: A Public Health Concern

Siddique

Fardows²,

Farhana

et al. 2016

J Enam Med Col

View full text Add to dashboard Cite

show abstract

“…A number of researches have been successfully conducted on the development of vaccines [61,62]. Experiments have been conducted also in African green monkeys [63].…”

Section: Preventionmentioning

confidence: 99%

Nipah Virus

Giangaspero¹

2013

Trop Med Surg

View full text Add to dashboard Cite

Natural HostFruit bats (Macrochiroptera) of the family Pteropodidaeparticularly species belonging to the Pteropus genus-are the natural hosts for Nipah virus. There is no apparent disease in fruit bats. Bats belonging to the genus Pteropus are widely distributed. They live in the tropics and subtropics of Asia, including the Indian subcontinent, Australia, Indonesia, Madagascar, and a number of remote oceanic islands in both the Indian and Pacific Oceans.Among the genus Pteropus, the Indian Flying Fox (Pteropus giganteus) (wingspan 1.5 m and up to 1.2 kg) and the relatively smaller Greater short-nosed fruit bat or Short-nosed Indian fruit bat (Cynopterus sphinx) (wingspan 48 cm), widespread and very common AbstractNipah virus is an emerging zoonosis with the potential to cause significant morbidity and mortality in humans and major economic and public health impacts. According to World Organisation for Animal Health (Office International des Épizooties: OIE), Nipah virus is a notifiable disease of importance to international trade.

show abstract

A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats

Cited by 114 publications

References 28 publications

Henipavirus: A Review of Laboratory Animal Pathology

Henipavirus: A Review of Laboratory Animal Pathology

Nipah Virus: A Public Health Concern

Nipah Virus

Contact Info

Product

Resources

About